PharmAust has success with gelatin encapsulated liquid monepantel
Clinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its anti-cancer trialling goals with treatment naïve B cell lymphoma.
Previously, PharmAust demonstrated that six of seven dogs with treatment-naïve B cell lymphoma achieved stable disease, or progression free survival, with reductions in tumour size following 14 consecutive days of gelatin encapsulated liquid monepantel treatment.
PharmAust is now repeating this study with the newly developed high dose and highly palatable GMP monepantel tablet formulation.
This comes on the back of a busy period for PharmAust on the corporate front with the recent appointment of experienced pharmaceutical and healthcare executive Colin La Galia has joined Epichem, a wholly owned subsidiary of PharmAust, as its new chief executive officer
The company’s success has been reflected in its share price performance over the last six months as it increased from 3.3 cents to a 12 month high of 17 cents in September.
Weakness in broader equity markets appeared to be central to the retracement in October, but with the company trading in the vicinity of 10 cents, it is still up about 200% since May.
Funds raised to accelerate human clinical trials
PharmAust also raised $2.4 million in October through a placement at an offer price of 12 cents per share with a significant proportion of the proceeds be used to accelerate human clinical trials of Monepantel.
From a broader perspective, PharmAust specialises in repurposing marketed drugs lowering the risks and costs of development.
The group’s subsidiary, Epichem, is a successful contract medicinal chemistry company that is forecasting $4.2m revenues in FY2019/20.
As the company’s lead drug candidate, Monepantel is a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.
The drug has been evaluated in Phase 1 clinical trials in humans and dogs, and it was well tolerated, producing a significant reduction in key prognostic biomarkers.
PharmAust is uniquely positioned to commercialise Monepantel for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.
Eligible dogs recruited from Sydney and Melbourne
A collaboration agreement between PharmAust and U-Vet in Werribee, whereby the University of Melbourne’s Department of Veterinary Clinical Sciences is the managing body, will assist in the recruitment of eligible dogs both from Melbourne and areas further afield.
All inventory, including antibodies and blood collection tubes have arrived on site.
A similar hub and spoke system is being employed in Sydney through the Animal Referral Hospital in Homebush, the body that conducted the previous trial using the gelatin encapsulated liquid capsules to successfully treat pet owners’ dogs with cancer.
Management hopes to replicate this type of system in other geographic areas, enabling local veterinarians to facilitate recruitment.
Trial data release will occur when a clear and meaningful trend becomes apparent and this will depend upon dog recruitment rates across the participating sites, highlighting the importance of scale in terms of the number of veterinary sites involved.
PharmAust anticipates an update to the market next month.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.